Ask about this productRelated genes to: VEGFA antibody
- Gene:
- VEGFA NIH gene
- Name:
- vascular endothelial growth factor A
- Previous symbol:
- VEGF
- Synonyms:
- VEGF-A, VPF
- Chromosome:
- 6p21.1
- Locus Type:
- gene with protein product
- Date approved:
- 1994-01-10
- Date modifiied:
- 2016-10-05
Related products to: VEGFA antibody
Related articles to: VEGFA antibody
- Gastric cancer has remained as a top ranked human malignancy showing both high morbidity and mortality, especially in Asian countries. Recent advances have revealed actionable targets for clinical gastric cancer therapy, including epidermal growth factor receptor 2 (HER2) and vascular endothelial growth factor receptor (VEGFR), thus calling for further investigation of potential therapeutic targets. Platelet-activating factor acetylhydrolase IB subunit alpha1 (PAFAH1B3) functions to remove the acetyl group from platelet-activating factor and is implicated in multiple diseases including cancer. However, the exact roles and underlying mechanisms of PAFAH1B3 in gastric cancer are incompletely investigated. By combining bioinformatic and gastric cancer tissue analyses, we confirmed that PAFAH1B3 was upregulated in gastric cancer and reversely correlated with patient prognosis showing significant association with tumor stages and metastasis. PAFAH1B3 knockdown rendered suppressed proliferation and migration, but enhanced apoptosis of gastric cancer cells. Transcriptomic profiling of control and PAFAH1B3 knockdown cells revealed VEGFA as a downstream effector, the overexpression of which effectively rescued defects imposed by PAFAH1B3 knockdown. Further investigation showed that PAFAH1B3 coordinated with the transcription factor E2F8 to promote VEGFA transcription. Importantly, in xenograft animal models, PAFAH1B3 overexpression significantly enhanced tumorigenesis, while VEGFA knockdown effectively suppressed gastric cancer xenograft growth. Therefore, our findings suggest that the PAFAH1B3/E2F8/VEGFA pathway plays an important role in gastric cancer progression, which can be targeted to design novel therapeutic strategies against gastric cancer. - Source: PubMed
Publication date: 2026/05/14
Liu ZhenhuaXiu YufangZhang ShanniJiang KeqiuZhang XiaoWang HaoDu JianyuZhang YingqiuKong Meng - Osteosarcoma (OS) is a very aggressive malignant neoplasm characterized by significant metastases and a deficiency of treatment targets. Therefore, it is urgent to find new therapeutic mechanisms and targets for OS. We assessed the capability of chromobox homolog 4 (CBX4) to modulate OS growth using in vivo and in vitro dual tests utilizing short hairpin RNA technology, 3-dimensional tumor sphere building, immunofluorescence co-localization, and other biotechnological methods. Our findings indicated that CBX4 was overexpressed in OS tissues, and the silencing of CBX4 markedly reduced OS cell proliferation, migration, and invasion. CBX4 modulates vasculogenic mimicry through its influence on yes1 associated transcriptional regulator (YAP1) and neuropilin-2/vascular endothelial growth factor A (NRP2/VEGFA) pathway, hence promoting angiogenic activity, a mechanism perhaps linked to CBX4's role in regulating mitochondrial autophagy. CBX4 affects vasculogenic mimicry by regulating the YAP1 and NRP2/VEGFA pathways and promotes the OS process. CBX4 may serve as a novel biomarker for OS, potentially offering innovative approaches for early diagnosis and tailored therapy of OS. SIGNIFICANCE STATEMENT: Osteosarcoma (OS) is a very aggressive malignant neoplasm characterized by significant metastases and a deficiency of treatment targets. Therefore, it is urgent to find new therapeutic mechanisms and targets for OS. Chromobox homolog 4 may serve as a novel biomarker for OS, potentially offering innovative approaches for early diagnosis and tailored therapy of OS. - Source: PubMed
Publication date: 2026/04/14
Gui HaoranLi Bo - Matching adjusted network meta-analyses (NMA) provide an established method to indirectly compare treatments across trials that share a common comparator. In this exploratory analysis, we conducted a matching-adjusted NMA to compare the efficacy of faricimab with aflibercept 8 mg for treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) via the common comparator of aflibercept 2 mg during the first 12 weeks of treatment when all agents are dosed equally. - Source: PubMed
Publication date: 2026/05/15
Lim Jennifer ILeng TheodoreSiedlecki JakobLupidi MarcoWells John AKeane Pearse ANudleman EricMar FlorieGibson KaraMargaron PhilippeTabano DavidBührer ChristianHolekamp Nancy - Endometriosis is a chronic gynecological disease characterized by the presence of endometrial tissue outside the uterine cavity, affecting approximately 10% of women of reproductive age. Vascular endothelial growth factor (VEGF) and cancer antigen 125 (CA125) have been proposed as potential biomarkers in endometriosis; however, evidence regarding their association with disease stage and pain severity remains limited, particularly in the Indonesian population. The aim of this study was to evaluate the relationship between peritoneal fluid VEGF and serum CA125 levels with endometriosis stage and pain severity. A cross-sectional study was conducted involving patients with surgically and histopathologically confirmed endometriosis who underwent laparoscopy or laparotomy at Dr. Zainoel Abidin Hospital, Banda Aceh, between February and July 2025. Peritoneal fluid VEGF and serum CA125 levels were measured using enzyme-linked immunosorbent assay and chemiluminescence immunoassay, respectively. Endometriosis stage was classified according to the revised American Society for Reproductive Medicine (rASRM) criteria, and pain severity was assessed using the Numeric Rating Scale. Statistical analyses included Spearman's correlation and receiver operating characteristic (ROC) curve analysis. Our data suggested no significant correlation between VEGF levels and endometriosis stage ( = 0.042; = 0.813). Peritoneal fluid VEGF levels showed a moderate positive correlation with pain severity ( = 0.505; < 0.05), and ROC analysis identified an optimal cut-off value of 39.45 pg/mL, with a sensitivity of 73.68% and specificity of 73.33% for distinguishing severe pain from mild-to-moderate pain. Serum CA125 levels demonstrated a significant positive correlation with endometriosis stage ( = 0.422; = 0.013), and ROC analysis yielded an optimal cut-off value of 32.45 U/mL, with a sensitivity of 86.95% and a specificity of 63.64% for distinguishing stage IV endometriosis from lower stages. No significant correlation was observed between CA125 levels and pain severity ( = 0.186; = 0.292). This study represents the first report from Indonesia to simultaneously evaluate peritoneal fluid VEGF and serum CA125 in relation to endometriosis stage and pain severity. This study highlights that CA125 is primarily associated with endometriosis stage, whereas VEGF is more closely related to pain severity, supporting their complementary roles in endometriosis assessment. - Source: PubMed
Publication date: 2026/01/19
Sujudi AkmalRusnaidi RusnaidiDewi Tgk PuspaRajuddin RajuddinSeptivera Yusra - Endometriosis affects approximately 10-15% of reproductive-age women and up to 70% of those with chronic pelvic pain, with diagnosis typically relying on invasive laparoscopy with histopathological confirmation. Cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) are central mediators of the inflammatory and angiogenic pathways underpinning endometriosis pathogenesis, making them promising candidates for non- invasive biomarkers. This study aimed to analyze the correlation between serum COX-2 and VEGF concentrations and endometriosis severity to evaluate their potential utility as non-invasive biomarkers. A cross-sectional study was conducted among women with confirmed endometriosis at Dr. Zainoel Abidin General Hospital in Banda Aceh, Indonesia, in 2025. Peripheral blood samples were collected preoperatively, and serum COX-2 and VEGF concentrations were quantified using ELISA. Endometriosis severity was classified according to the American Society for Reproductive Medicine staging system. Correlation analyses were performed to assess associations between biomarker levels and disease stage, and diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis to determine the area under the curve (AUC) values, optimal cut-off points, sensitivity, and specificity. Twenty-eight patients were included, with the mean COX-2 and VEGF levels being 1.16 ± 1.28 ng/mL and 266.50 ± 72.91 pg/mL, respectively. VEGF demonstrated a strong and statistically significant correlation with endometriosis staging ( = 0.744, < 0.001), while COX-2 showed a limited correlation that did not reach statistical significance ( = 0.367, = 0.055). The ROC analysis further highlighted VEGF's superior diagnostic performance, with an AUC of 0.975 (95%CI: 0.926-1.000, < 0.001) compared with COX-2 (AUC 0.734; 95%CI: 0.518-0.950, = 0.057). The optimal VEGF threshold of 221 pg/mL yielded 90% sensitivity and 100% specificity, whereas the COX-2 threshold of 0.675 ng/mL provided 80% sensitivity and 62.5% specificity. These findings indicate that VEGF is a highly promising non-invasive biomarker for assessing endometriosis severity and may support the development of improved diagnostic approaches for endometriosis management. - Source: PubMed
Publication date: 2026/01/13
Aslam AgaRajuddin RajuddinMunizar MunizarRusnaidi RusnaidiHasanuddin Hasanuddin